Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam monotherapy vs combination therapy for carbapenem-resistant organism infections
ChiCTR2600117034Phase 4Not yet recruiting
- Sponsor
- The First People's Hospital of Yunnan Province
- Start
- Jan 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ceftazidime + avibactam in carbapenem-resistant Enterobacterales infection, Pseudomonal infection and bacterial disease (2 arms), sponsored by The First People's Hospital of Yunnan Province. Primary endpoints: Clinical cure rate, Microbial clearance rate (day 7 of treatment) and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ceftazidime + avibactam
03
Conditions
carbapenem-resistant Enterobacterales infectionPseudomonal infectionbacterial disease
Beyond the preview
Go deeper on ChiCTR2600117034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117034.